CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced today that it obtained exclusive, worldwide rights from Robarts Research Institute (London, Ontario, Canada) for NamPRT (also known as Visfatin), an important genetic driver of cellular stress resistance and longevity in mammals.
